237 related articles for article (PubMed ID: 26302359)
1. Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds.
Somani AA; Thelen K; Zheng S; Trame MN; Coboeken K; Meyer M; Schnizler K; Ince I; Willmann S; Schmidt S
Br J Clin Pharmacol; 2016 Jan; 81(1):137-47. PubMed ID: 26302359
[TBL] [Abstract][Full Text] [Related]
2. Development and applications of a physiologically-based model of paediatric oral drug absorption.
Johnson TN; Bonner JJ; Tucker GT; Turner DB; Jamei M
Eur J Pharm Sci; 2018 Mar; 115():57-67. PubMed ID: 29309876
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Physiologically Based Pharmacokinetic Models to Predict the Absorption of BCS Class I Drugs in Different Pediatric Age Groups.
Liu XI; van den Anker JN; Burckart GJ; Dallmann A
J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S94-S107. PubMed ID: 34185902
[TBL] [Abstract][Full Text] [Related]
4. Establishment of modified biopharmaceutics classification system absorption model for oral Traditional Chinese Medicine (Sanye Tablet).
Li H; Cao X; Liu Y; Liu T; Wang M; Ren X; Dou Z
J Ethnopharmacol; 2019 Nov; 244():112148. PubMed ID: 31400507
[TBL] [Abstract][Full Text] [Related]
5. Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models.
Hansmann S; Darwich A; Margolskee A; Aarons L; Dressman J
J Pharm Pharmacol; 2016 Dec; 68(12):1501-1515. PubMed ID: 27781273
[TBL] [Abstract][Full Text] [Related]
6. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.
Tsume Y; Langguth P; Garcia-Arieta A; Amidon GL
Biopharm Drug Dispos; 2012 Oct; 33(7):366-77. PubMed ID: 22815122
[TBL] [Abstract][Full Text] [Related]
7. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
8. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low-birth-weight infants.
Ohlsson A; Shah PS
Cochrane Database Syst Rev; 2015 Mar; (3):CD010061. PubMed ID: 25758061
[TBL] [Abstract][Full Text] [Related]
9. Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses.
Chow EC; Talattof A; Tsakalozou E; Fan J; Zhao L; Zhang X
AAPS J; 2016 Nov; 18(6):1500-1511. PubMed ID: 27520379
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
11. Potential for pharmaceutical excipients to impact absorption: A mechanistic review for BCS Class 1 and 3 drugs.
Flanagan T
Eur J Pharm Biopharm; 2019 Aug; 141():130-138. PubMed ID: 31128247
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates.
El-Mashad AE; El-Mahdy H; El Amrousy D; Elgendy M
Eur J Pediatr; 2017 Feb; 176(2):233-240. PubMed ID: 28004188
[TBL] [Abstract][Full Text] [Related]
13. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF
Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626
[TBL] [Abstract][Full Text] [Related]
14. Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen.
Potthast H; Dressman JB; Junginger HE; Midha KK; Oeser H; Shah VP; Vogelpoel H; Barends DM
J Pharm Sci; 2005 Oct; 94(10):2121-31. PubMed ID: 16136567
[TBL] [Abstract][Full Text] [Related]
15. Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugs.
Melillo N; Aarons L; Magni P; Darwich AS
J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):27-42. PubMed ID: 30552544
[TBL] [Abstract][Full Text] [Related]
16. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines.
Charalabidis A; Sfouni M; Bergström C; Macheras P
Int J Pharm; 2019 Jul; 566():264-281. PubMed ID: 31108154
[TBL] [Abstract][Full Text] [Related]
17. Regional intestinal drug permeation: biopharmaceutics and drug development.
Lennernäs H
Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
[TBL] [Abstract][Full Text] [Related]
18. Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system.
Del Moral Sanchez JM; Gonzalez-Alvarez I; Cerda-Revert A; Gonzalez-Alvarez M; Navarro-Ruiz A; Amidon GL; Bermejo M
Br J Clin Pharmacol; 2018 Oct; 84(10):2231-2241. PubMed ID: 29846973
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Excipients on the Permeability of BCS Class III Compounds and Implications for Biowaivers.
Parr A; Hidalgo IJ; Bode C; Brown W; Yazdanian M; Gonzalez MA; Sagawa K; Miller K; Jiang W; Stippler ES
Pharm Res; 2016 Jan; 33(1):167-76. PubMed ID: 26286187
[TBL] [Abstract][Full Text] [Related]
20. Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol).
Kalantzi L; Reppas C; Dressman JB; Amidon GL; Junginger HE; Midha KK; Shah VP; Stavchansky SA; Barends DM
J Pharm Sci; 2006 Jan; 95(1):4-14. PubMed ID: 16307451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
